New Kalorama Report Says In Vitro Diagnostic Market Reaches 54.6 Billion - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
New Kalorama Report Says In Vitro Diagnostic Market Reaches 54.6 Billion Technology, Emerging Markets Show Surprising Growth


New Kalorama Report Says In Vitro Diagnostic Market Reaches 54.6 Billion

Technology, Emerging Markets Show Surprising Growth

PR Newswire

NEW YORK, Aug. 14, 2014 /PRNewswire/ -- The world market for diagnostics is estimated at $54.6 billion in 2013, according to Kalorama Information.  The market is expected to grow 4% annually and reach $65 billion by 2018.  This includes all laboratory and hospital-based products, and OTC product sales.  Kalorama revealed the market estimates in its biennial survey of the IVD industry, The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition

Kalorama Information Logo

The survey can be obtained at  http://www.kaloramainformation.com/redirect.asp?progid=86544&productid=8326563

New technology is leading the charge, according to Kalorama.  Diagnostic laboratory technology has changed dramatically in the past few years, due to the publication of the human genome project and advances in functional genomics, bioinformatics, miniaturization and microelectronics. 

"Not three years ago it would have been almost inconceivable to see research technologies such as genome sequencing and mass spectroscopy play a pivotal role in improving lab medicine," said Shara Rosen, Kalorama's lead diagnostic analyst and the author of the report.  "Their influence is felt in personalized medicine, inherited diseases, pathogen detection, antibiotic resistance testing, blood banking and much more to come."

According to the report, this phenomenon has seen the major vendors of these technologies enter the IVD market.  Life Technologies, Illumina, Affymetrix, Bruker Daltonics, PerkinElmer/Caliper and others have all launched clinical tests and test services.

Another finding in the report is that emerging markets have taken off.  All of the major IVD companies reported at least 25% increase in their sales in China and growth in the top seven emerging markets: Brazil, Turkey, Korea, India, Russia and Mexico. 

"We knew that these were target markets but the double-digit results in China were surprising," said Bruce Carlson, Publisher of Kalorama Information.  "These countries continue to invest in healthcare infrastructure and insurance coverage and IVD is part of that."

On the supply side, labs are challenged to add new tests with little increase in financial and human resources.  For most labs it may even mean doing more with less.

The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition presents the trends, technologies, customer needs and major suppliers with an eye on how they are shaping the IVD industry.  The survey can be found along with other industry renowned research from Kalorama at http://www.kaloramainformation.com/

About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.

Contact:
Bruce Carlson
212.807.2622
bcarlson@kaloramainformation.com

Logo - http://photos.prnewswire.com/prnh/20140801/132634

 

SOURCE Kalorama Information

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here